SBK
BLPH

Steven B. Klinsky’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Steven B. Klinsky’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$38.5M Hold
323,992
– – 17.48% 3
2015
Q1 		$44.6M Buy
+323,992
New +$50.4M 20.33% 3

Other funds holding BLPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Steven B. Klinsky's BLPH Position: Q2 2015 in Review

Steven B. Klinsky held its Bellerophon Therapeutics, Inc. (BLPH) position steady in Q2 2015 at 323,992 shares worth $38.5M. The position accounts for 17.48% of the portfolio, ranked #3.

Steven B. Klinsky first reported a position in BLPH in Q1 2015 and has held it in 2 quarters since. The position peaked at $44.6M in Q1 2015. 20 funds tracked by Wall St. Rank hold BLPH as of Q2 2015.

  • Steven B. Klinsky held 323,992 shares of Bellerophon Therapeutics, Inc. worth $38.5M as of Q2 2015.
  • Steven B. Klinsky left its Bellerophon Therapeutics, Inc. share count unchanged in Q2 2015.
  • Bellerophon Therapeutics, Inc. made up 17.48% of Steven B. Klinsky's portfolio in Q2 2015, its #3 holding.
  • Steven B. Klinsky first reported a position in Bellerophon Therapeutics, Inc. in Q1 2015 and has held it in 2 quarters since.
  • Steven B. Klinsky's Bellerophon Therapeutics, Inc. position peaked at $44.6M in Q1 2015.
  • 20 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2015.

Based on Steven B. Klinsky's 13F filing for Q2 2015, filed 14 Aug 2015.